Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.

Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2007) 1.81

The significance of different formulations of aerosolized colistin. Crit Care (2005) 0.76

Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic/Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrob Agents Chemother (2017) 0.75

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother (1999) 4.23

Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect (2004) 3.71

Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med (2003) 2.13

Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother (2004) 1.99

Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med (2004) 1.92

The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med (2001) 1.61

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care (2005) 1.58

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros (2004) 1.14

Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41

Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA (2004) 2.90

Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med (2007) 2.58

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs (2013) 2.33

Comparative review of the carbapenems. Drugs (2007) 2.06

Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis (2004) 1.95

Linezolid: a review of safety and tolerability. J Infect (2009) 1.95

The changing face of Klebsiella pneumoniae infections in the community. Int J Antimicrob Agents (2007) 1.73

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs (2009) 1.41

Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg Infect Dis (2005) 1.32

Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae. Scand J Infect Dis (2007) 1.29

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs (2010) 1.29

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs (2014) 1.27

The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J (2007) 1.26

The pneumococcal pilus predicts the absence of Staphylococcus aureus co-colonization in pneumococcal carriers. Clin Infect Dis (2009) 1.23

Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther (2007) 1.23

Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis (2014) 1.17

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther (2012) 1.11

Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis (2009) 1.09

Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS One (2013) 1.05

Anti-infective research and development--problems, challenges, and solutions. Lancet Infect Dis (2007) 1.05

Comparison of community-acquired methicillin-resistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unit. Eur J Pediatr (2006) 1.05

Chemokine receptor 5 △32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis (2010) 1.03

Influenza epidemiology--past, present, and future. Crit Care Med (2010) 1.02

Parental Staphylococcus aureus carriage is associated with staphylococcal carriage in young children. Pediatr Infect Dis J (2009) 0.99

Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther (2006) 0.99

Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther (2007) 0.98

Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. J Antimicrob Chemother (2004) 0.97

Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health (2014) 0.96

Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children? Clin Infect Dis (2008) 0.96

Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents (2013) 0.96

Staphylococcus aureus bacteremia, risk factors, complications, and management. Crit Care Clin (2013) 0.95

In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from cocolonized versus noncocolonized children. J Clin Microbiol (2007) 0.95

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs (2015) 0.94

Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother (2002) 0.93

An outbreak of Phialemonium infective endocarditis linked to intracavernous penile injections for the treatment of impotence. Clin Infect Dis (2005) 0.92

Adverse reactions to β-lactam antimicrobials. Expert Opin Drug Saf (2012) 0.92

A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections. Treat Respir Med (2006) 0.91

Pathophysiology of infective endocarditis. Curr Infect Dis Rep (2013) 0.91

Septic arthritis due to Roseomonas gilardii in an immunocompetent adolescent. J Med Microbiol (2009) 0.91

Role of agr (RNAIII) in Staphylococcus aureus adherence to fibrinogen, fibronectin, platelets and endothelial cells under static and flow conditions. J Med Microbiol (2002) 0.90

Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc (2005) 0.90

Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. Hum Vaccin Immunother (2013) 0.89

Novel agents for resistant Gram-positive infections--a review. Int J Infect Dis (2002) 0.88

Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther (2008) 0.88

Reduction in antibiotic use following a cluster randomized controlled multifaceted intervention: the Israeli judicious antibiotic prescription study. Clin Infect Dis (2011) 0.87

Overview of seizure-inducing potential of doripenem. Drug Saf (2009) 0.87

Is in vitro antibiotic combination more effective than single-drug therapy against anthrax? Antimicrob Agents Chemother (2005) 0.85

Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. Int J Antimicrob Agents (2013) 0.85

Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol (2008) 0.84

Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother (2014) 0.83

Infective endocarditis in the intensive care unit. Crit Care Clin (2013) 0.83

Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies. BMC Infect Dis (2014) 0.82

Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol (2008) 0.81

Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007. J Med Microbiol (2012) 0.80

Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers. Curr Opin Infect Dis (2002) 0.80

Endogenous endophthalmitis caused by hypermucoviscous Klebsiella pneumoniae: an emerging disease in Southeast Asia and beyond. Curr Infect Dis Rep (2008) 0.80

Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). J Antimicrob Chemother (2013) 0.80

Changing parents' opinions regarding antibiotic use in primary care. Eur J Pediatr (2010) 0.79

Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. J Antimicrob Chemother (2003) 0.78

Independent risk factors for carriage of penicillin-non-susceptible Streptococcus pneumoniae. Scand J Infect Dis (2003) 0.78

Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia. Expert Opin Drug Metab Toxicol (2013) 0.77

Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother (2013) 0.77

Are drug clinical trials broadly applicable? The case of staphylococcal bacteraemia. Int J Antimicrob Agents (2009) 0.77

Genetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from Afghanistan. PLoS Negl Trop Dis (2012) 0.77

Fungal Endocarditis. Curr Infect Dis Rep (2004) 0.77

Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2005) 0.76

Diabetes mellitus and pyogenic liver abscess: risk and prognosis. Clin Infect Dis (2007) 0.76

HAP/VAP: Simpler may be better. Can J Infect Dis Med Microbiol (2008) 0.75

Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother (2003) 0.75

Targeting the chemokine receptor CCR5: good for HIV, what about other viruses? J Infect Dis (2011) 0.75

Resistant organisms and otitis media. Pediatr Infect Dis J (2005) 0.75